Drugs / IL-15-armored CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07509086 | Dec 2025 → Jul 2028 expected | plasma cell leukemia, refractory plasma cell neoplasm | The First Hospital of Jilin University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-15-armored CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07509086 ↗ |
| Modality | Cell therapy | “IL-15-armored CAR-T cells are autologous T lymphocytes genetically engineered to express a chimeric antigen receptor along with IL-15.” NCT07509086 ↗ |
| Target | CD19 | “CD19/BCMA dual-targeted: 1.0/1.5/2.0 × 10\^6 CAR-T cells” NCT07509086 ↗ |
| Target | GPRC5D | “GPRC5D-targeted: 1.0/2.0/3.0 × 10\^6 CAR-T cells.” NCT07509086 ↗ |